HIV-derived vectors for therapy and vaccination against HIV

Vaccine

Volumn 30, Issue 15, 2012, Pages 2499-2509

  Di Nunzio, F ^a   Felix T ^a   Arhel, N J ^a   Nisole, S ^a   Charneau, P ^a   Beignon, A S ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

AIDS HIV vaccine; Lentiviral vectors; Pre clinical studies

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LENTIVIRUS VECTOR; LIVE VACCINE; NEF PROTEIN; POL PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW CELL; CANARYPOX VIRUS; CD4+ T LYMPHOCYTE; DISEASE TRANSMISSION; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOTHERAPY; LONG TERMINAL REPEAT; MOLONEY LEUKEMIA ONCOVIRUS; MUTAGENESIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SAFETY; SIMIAN IMMUNODEFICIENCY VIRUS; SINDBIS VIRUS; SPLEEN FOCUS FORMING VIRUS; VACCINATION; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS LOAD; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; GENE THERAPY; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; LENTIVIRUS;

EID: 84858294455     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.089     Document Type: Review

References (146)

1. Moir S., Chun T.W., Fauci A.S. Pathogenic mechanisms of HIV disease. Annu Rev Pathol 2011, 6(February):223-248.
2. McCune J.M. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001, 410(April (6831)):974-979.
3. Simon V., Ho D.D., Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006, 368(August (9534)):489-504.
4. Miller A.D. Development and applications of retroviral vectors. Retroviruses 1997, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. J.M. Coffin, S.H. Hughes, H.E. Varmus (Eds.).
5. Poznansky M., Lever A., Bergeron L., Haseltine W., Sodroski J. Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector. J Virol 1991, 65(January (1)):532-536.
6. Yee J.K., Miyanohara A., LaPorte P., Bouic K., Burns J.C., Friedmann T. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994, 91(September (20)):9564-9568.
7. Naldini L., Blömer U., Gallay P., Ory D., Mulligan R., Gage F.H., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272(April (5259)):263-267.
8. Zennou V., Petit C., Guetard D., Nerhbass U., Montagnier L., Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000, 101(April (2)):173-185.
9. Mitrophanous K., Yoon S., Rohll J., Patil D., Wilkes F., Kim V., et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 1999, 6(November (11)):1808-1818.
10. Nègre D., Cosset F.L. Vectors derived from simian immunodeficiency virus (SIV). Biochimie 2002, 84(November (11)):1161-1171.
11. Gilbert J.R., Wong-Staal F. HIV-2 and SIV vector systems. Somat Cell Mol Genet 2001, 26(November (1-6)):83-98.
12. Saenz D.T., Poeschla E.M. FIV: from lentivirus to lentivector. J Gene Med 2004, 6(February (Suppl. 1)):S95-S104.
13. Zufferey R., Nagy D., Mandel R.J., Naldini L., Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997, 15(September (9)):871-875.
14. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302(October (5644)):415-419.
15. Gaspar H.B., Cooray S., Gilmour K.C., Parsley K.L., Adams S., Howe S.J., et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011, 3(August (97)):97ra79.
16. Zhou S., Mody D., DeRavin S.S., Hauer J., Lu T., Ma Z., et al. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood 2010, 116(August (6)):900-908.
17. Ginn S.L., Liao S.H., Dane A.P., Hu M., Hyman J., Finnie J.W., et al. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression. Mol Ther 2010, 18(May (5)):965-976.
18. Modlich U., Navarro S., Zychlinski D., Maetzig T., Knoess S., Brugman M.H., et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009, 17(November (11)):1919-1928.
19. Sirven A., Ravet E., Charneau P., Zennou V., Coulombel L., Guétard D., et al. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol Ther 2001, 3(April (4)):438-448.
20. Symonds G.P., Johnstone H.A., Millington M.L., Boyd M.P., Burke B.P., Breton L.R. The use of cell-delivered gene therapy for the treatment of HIV/AIDS. Immunol Res 2010, 48(December (1-3)):84-98.
21. Hütter G., Nowak D., Mossner M., Ganepola S., Müssig A., Allers K., et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009, 360(February (7)):692-698.
22. Allers K., Hütter G., Hofmann J., Loddenkemper C., Rieger K., Thiel E., et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 2011, 117(March (10)):2791-2799.
23. Kitchen S., Shimizu S., An D.S. Stem cell-based anti-HIV therapy. Virology 2011, 411:260-272.
24. Carter C.C., Onafuwa-Nuga A., McNamara L.A., Riddell J.T., Bixby D., Savona M.R., et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010, 16:446-451.
25. An D.S., Donahue R.E., Kamata M., Poon B., Metzger M., Mao S.H., et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci USA 2007, 104(August (32)):13110-13115.
26. Luo X.M., Maarschalk E., O'Connell R.M., Wang P., Yang L., Baltimore D. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 2009, 113(February (7)):1422-1431.
27. Joseph A., Zheng J.H., Chen K., Dutta M., Chen C., Stiegler G., et al. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralising antibody. J Virol 2010, 84(13):6645-6653.
28. Joseph A., Zheng J.H., Follenzi A., Dilorenzo T., Sango K., Hyman J., et al. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J Virol. 2008, 82(March (6)):3078-3089.
29. Yang L., Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci USA 2005, 102(March (12)):4518-4523.
30. Barsov E.V., Trivett M.T., Minang J.T., Sun H., Ohlen C., Ott D.E. Transduction of SIV-specific TCR genes into rhesus macaque CD8 T cells conveys the ability to suppress SIV replication. PLoS One 2011, 6(8):e23703.
31. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326(November (5954)):818-823.
32. Cavazzana-Calvo M., Payen E., Negre O., Wang G., Hehir K., Fusil F., et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010, 467(September (7313)):318-322.
33. Levine B.L., Humeau L.M., Boyer J., MacGregor R.R., Rebello T., Lu X., et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006, 103(November (46)):17372-17377.
34. DiGiusto D.L., Krishnan A., Li L., Li H., Li S., Rao A., et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010, 2(June (36)):36ra43.
35. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(November (9653)):1881-1893.
36. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372(November (9653)):1894-1905.
37. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(December (23)):2209-2220.
38. Breckpot K., Emeagi P., Dullaers M., Michiels A., Heirman C., Thielemans K. Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum Gene Ther 2007, 18(June (6)):536-546.
39. Arce F., Rowe H.M., Chain B., Lopes L., Collins M.K. Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization. Mol Ther 2009, 17(September (9)):1643-1650.
40. Esslinger C., Chapatte L., Finke D., Miconnet I., Guillaume P., Lévy F., et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 2003, 111(June (11)):1673-1681.
41. Pichlmair A., Diebold S.S., Gschmeissner S., Takeuchi Y., Ikeda Y., Collins M.K., et al. Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. J Virol 2007, 81(January (2)):539-547.
42. Breckpot K., Escors D., Arce F., Lopes L., Karwacz K., Van Lint S., et al. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol 2010, 84(June (11)):5627-5636.
43. Rossetti M., Gregori S., Hauben E., Brown B.D., Sergi L.S., Naldini L., et al. HIV-1-derived lentiviral vectors directly activate plasmacytoid dendritic cells, which in turn induce the maturation of myeloid dendritic cells. Hum Gene Ther 2011, 22(February (2)):177-188.
44. He Y., Zhang J., Donahue C., Falo L.D. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006, 24(May (5)):643-656.
45. Furmanov K., Elnekave M., Lehmann D., Clausen B.E., Kotton D.N., Hovav A.H. The role of skin-derived dendritic cells in CD8+ T cell priming following immunization with lentivectors. J Immunol 2010, 184(May (9)):4889-4897.
46. Goold H.D., Escors D., Conlan T.J., Chakraverty R., Bennett C.L. Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors. J Immunol 2011, 186(April (8)):4565-4572.
47. Larsson M., Beignon A.S., Bhardwaj N. DC-virus interplay: a double edged sword. Semin Immunol 2004, 16(June (3)):147-161.
48. VandenDriessche T., Thorrez L., Naldini L., Follenzi A., Moons L., Berneman Z., et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002, 100(August (3)):813-822.
49. Rowe H.M., Lopes L., Ikeda Y., Bailey R., Barde I., Zenke M., et al. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol Ther 2006, 13(February (2)):310-319.
50. Firat H., Zennou V., Garcia-Pons F., Ginhoux F., Cochet M., Danos O., et al. Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J Gene Med 2002, 4(January-February (1)):38-45.
51. Colombetti S., Lévy F., Chapatte L. IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector. Blood 2009, 113(June (26)):6629-6637.
52. Iglesias M.C., Frenkiel M.P., Mollier K., Souque P., Despres P., Charneau P. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J Gene Med 2006, 8(March (3)):265-274.
53. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001, 106(September (5)):539-549.
54. Beignon A.S., Mollier K., Liard C., Coutant F., Munier S., Rivière J., et al. Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques. J Virol 2009, 83(November (21)):10963-10974.
55. Buffa V., Negri D.R., Leone P., Borghi M., Bona R., Michelini Z., et al. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. Viral Immunol 2006, 19(4):690-701.
56. Buffa V., Negri D.R., Leone P., Bona R., Borghi M., Bacigalupo I., et al. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice. J Gen Virol 2006, 87(June (Pt. 6)):1625-1634.
57. Iglesias M.C., Mollier K., Beignon A.S., Souque P., Adotevi O., Lemonnier F., et al. Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol Ther 2007, 15(June (6)):1203-1210.
58. Dai B., Yang L., Yang H., Hu B., Baltimore D., Wang P. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci USA 2009, 106(December (48)):20382-20387.
59. Limberis M.P., Bell C.L., Heath J., Wilson J.M. Activation of transgene-specific T cells following lentivirus-mediated gene delivery to mouse lung. Mol Ther 2010, 18(January (1)):143-150.
60. Gibbs J.S., Regier D.A., Desrosiers R.C. Construction and in vitro properties of SIVmac mutants with deletions in nonessential genes. AIDS Res Hum Retroviruses 1994, 10(May (5)):607-616.
61. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258(December (5090)):1938-1941.
62. Schmitz J.E., Johnson R.P., McClure H.M., Manson K.H., Wyand M.S., Kuroda M.J., et al. Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol 2005, 79(July (13)):8131-8141.
63. Wyand M.S., Manson K., Montefiori D.C., Lifson J.D., Johnson R.P., Desrosiers R.C. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999, 73(October (10)):8356-8363.
64. Reynolds M.R., Weiler A.M., Weisgrau K.L., Piaskowski S.M., Furlott J.R., Weinfurter J.T., et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 2008, 205(October (11)):2537-2550.
65. Das A.T., Jeeninga R.E., Berkhout B. Possible applications for replicating HIV 1 vectors. HIV Ther 2010, 4(May (3)):361-369.
66. Gorry P.R., Churchill M., Learmont J., Cherry C., Dyer W.B., Wesselingh S.L., et al. Replication-dependent pathogenicity of attenuated nef-deleted HIV-1 in vivo. J Acquir Immune Defic Syndr 2007, 46(December (4)):390-394.
67. Baba T.W., Jeong Y.S., Pennick D., Bronson R., Greene M.F., Ruprecht R.M. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995, 267(March (5205)):1820-1825.
68. Koff W.C., Johnson P.R., Watkins D.I., Burton D.R., Lifson J.D., Hasenkrug K.J., et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006, 7(January (1)):19-23.
69. Kuate S., Stahl-Hennig C., ten Haaft P., Heeney J., Uberla K. Single-cycle immunodeficiency viruses provide strategies for uncoupling in vivo expression levels from viral replicative capacity and for mimicking live-attenuated SIV vaccines. Virology 2003, 313(September (2)):653-662.
70. Evans D.T., Bricker J.E., Sanford H.B., Lang S., Carville A., Richardson B.A., et al. Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. J Virol 2005, 79(June (12)):7707-7720.
71. Peng Y., Lin F.C., Verardi P.H., Jones L.A., McChesney M.B., Yilma T.D. Pseudotyped single-cycle simian immunodeficiency viruses expressing gamma interferon augment T-cell priming responses in vitro. J Virol 2007, 81(March (5)):2187-2195.
72. Tang Y., Swanstrom R. Development and characterization of a new single cycle vaccine vector in the simian immunodeficiency virus model system. Virology 2008, 372(March (1)):72-84.
73. Jia B., Ng S.K., DeGottardi M.Q., Piatak M., Yuste E., Carville A., et al. Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239. PLoS Pathog 2009, 5(January (1)):e1000272.
74. Ellenberger D., Wyatt L., Li B., Buge S., Lanier N., Rodriguez I.V., et al. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. Virology 2005, 340(September (1)):21-32.
75. Kuate S., Stahl-Hennig C., Stoiber H., Nchinda G., Floto A., Franz M., et al. Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus. Virology 2006, 351(July (1)):133-144.
76. Somogyi E., Xu J., Gudics A., Tóth J., Kovács A.L., Lori F., et al. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine 2011, 29(January (4)):744-753.
77. O'Neill E., Martinez I., Villinger F., Rivera M., Gascot S., Colon C., et al. Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. J Med Primatol 2002, 31(August (4-5)):217-227.
78. Cristillo A.D., Lisziewicz J., He L., Lori F., Galmin L., Trocio J.N., et al. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 2007, 366(September (1)):197-211.
79. Johnson R.P., Lifson J.D., Czajak S.C., Cole K.S., Manson K.H., Glickman R., et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 1999, 73(June (6)):4952-4961.
80. Barouch D.H., O'Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16(March (3)):319-323.
81. McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33(October (4)):542-554.
82. Lopes L., Dewannieux M., Takeuchi Y., Collins M.K. A lentiviral vector pseudotype suitable for vaccine development. J Gene Med 2011, 13(March (3)):181-187.
83. Schweizer M., Merten O.W. Large-scale production means for the manufacturing of lentiviral vectors. Curr Gene Ther 2010, 10(December (6)):474-486.
84. Annoni A., Battaglia M., Follenzi A., Lombardo A., Sergi-Sergi L., Naldini L., et al. The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells. Blood 2007, 110(September (6)):1788-1796.
85. Brown B.D., Sitia G., Annoni A., Hauben E., Sergi L.S., Zingale A., et al. In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood 2007, 109(April (7)):2797-2805.
86. Montini E., Cesana D., Schmidt M., Sanvito F., Ponzoni M., Bartholomae C., et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006, 24(June (6)):687-696.
87. Escors D., Lopes L., Lin R., Hiscott J., Akira S., Davis R.J., et al. Targeting dendritic cell signaling to regulate the response to immunization. Blood 2008, 111(March (6)):3050-3061.
88. Rowe H.M., Lopes L., Brown N., Efklidou S., Smallie T., Karrar S., et al. Expression of vFLIP in a lentiviral vaccine vector activates NF-{kappa}B, matures dendritic cells, and increases CD8+ T-cell responses. J Virol 2009, 83(February (4)):1555-1562.
89. Frecha C., Lévy C., Costa C., Nègre D., Amirache F., Buckland R., et al. Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J Virol 2011, 85(June (12)):5975-5985.
90. Yang L., Yang H., Rideout K., Cho T., Joo K.I., Ziegler L., et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008, 26(March (3)):326-334.
91. Yang H.G., Hu B.L., Xiao L., Wang P. Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma. Cancer Gene Ther 2011, 18(May (5)):370-380.
92. Ageichik A., Buchholz C.J., Collins M.K. Lentiviral vectors targeted to MHC II are effective in immunization. Hum Gene Ther 2011, (March).
93. Lopes L., Dewannieux M., Gileadi U., Bailey R., Ikeda Y., Whittaker C., et al. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol 2008, 82(January (1)):86-95.
94. Kimura T., Koya R.C., Anselmi L., Sternini C., Wang H.J., Comin-Anduix B., et al. Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol Ther 2007, 15(July (7)):1390-1399.
95. Dresch C., Edelmann S.L., Marconi P., Brocker T. Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. J Immunol 2008, 181(October (7)):4495-4506.
96. Buceta M., Galbete J.L., Kostic C., Arsenijevic Y., Mermod N. Use of human MAR elements to improve retroviral vector production. Gene Ther 2011, 18(January (1)):7-13.
97. Grandchamp N., Henriot D., Philippe S., Amar L., Ursulet S., Serguera C., et al. Influence of insulators on transgene expression from integrating and non-integrating lentiviral vectors. Genet Vaccines Ther 2011, 9(January (1)):1.
98. Uchida N., Washington K.N., Lap C.J., Hsieh M.M., Tisdale J.F. Chicken HS4 insulators have minimal barrier function among progeny of human hematopoietic cells transduced with an HIV1-based lentiviral vector. Mol Ther 2011, 19(January (1)):133-139.
99. Menzel O., Birraux J., Wildhaber B.E., Jond C., Lasne F., Habre W., et al. Biosafety in ex vivo gene therapy and conditional ablation of lentivirally transduced hepatocytes in nonhuman primates. Mol Ther 2009, 17(October (10)):1754-1760.
100. Sloan R.D., Wainberg M.A. The role of unintegrated DNA in HIV infection. Retrovirology 2011, 8(July):52.
101. Vargas J., Gusella G.L., Najfeld V., Klotman M.E., Cara A. Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 2004, 15(April (4)):361-372.
102. Banasik M.B., McCray P.B. Integrase-defective lentiviral vectors: progress and applications. Gene Ther 2010, 17(February (2)):150-157.
103. Philippe S., Sarkis C., Barkats M., Mammeri H., Ladroue C., Petit C., et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 2006, 103(November (47)):17684-17689.
104. Yáñez-Muñoz R.J., Balaggan K.S., MacNeil A., Howe S.J., Schmidt M., Smith A.J., et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006, 12(March (3)):348-353.
105. Coutant F., Frenkiel M.P., Despres P., Charneau P. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 2008, 3(12):e3973.
106. Negri D.R., Michelini Z., Baroncelli S., Spada M., Vendetti S., Buffa V., et al. Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 2007, 15(September (9)):1716-1723.
107. Hu B., Yang H., Dai B., Tai A., Wang P. Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity. Hum Gene Ther 2009, 20(December (12)):1652-1664.
108. Karwacz K., Mukherjee S., Apolonia L., Blundell M.P., Bouma G., Escors D., et al. Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 2009, 83(April (7)):3094-3103.
109. Hu B., Dai B., Wang P. Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity. Vaccine 2010, 28(September (41)):6675-6683.
110. Goujon C., Jarrosson-Wuillème L., Bernaud J., Rigal D., Darlix J.L., Cimarelli A. With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther 2006, 13(12):991-994.
111. Belshan M., Mahnke L.A., Ratner L. Conserved amino acids of the human immunodeficiency virus type 2 Vpx nuclear localization signal are critical for nuclear targeting of the viral preintegration complex in non-dividing cells. Virology 2006, 346:118-126.
112. Cheng X., Belshan M., Ratner L. Hsp40 facilitates nuclear import of the human immunodeficiency virus type 2 Vpx-mediated preintegration complex. J Virol 2008, 82:1229-1237.
113. Fletcher T.M, Brichacek B., Sharova N., Newman M.A., Stivahtis G., Sharp P.M., et al. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J 1996, 15(22):6155-6165.
114. Goujon C., Riviere L., Jarrosson-Wuilleme L., Bernaud J., Rigal D., Darlix J.L., et al. SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 2007, 4:2.
115. Fujita M., Otsuka M., Miyoshi M., Khamsri B., Nomaguchi M., Adachi A. Vpx is critical for reverse transcription of the human immunodeficiency virus type 2 genome in macrophages. J Virol 2008, 82:7752-7756.
116. Sharova N., Wu Y., Zhu X., Stranska R., Kaushik R., Sharkey M., et al. Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog 2008, 4:e1000057.
117. Srivastava S., Swanson S.K., Manel N., Florens L., Washburn M.P., Skowronski J. Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog 2008, 4:e1000059.
118. Bergamaschi A., Ayinde D., David A., Le Rouzic E., Morel M., Collin G., et al. The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. J Virol 2009, 83:4854-4860.
119. Laguette N., Sobhian B., Casartelli N., Ringeard M., Chable-Bessia C., Ségéral E., et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011, 474(7353):654-657.
120. Hrecka K., Hao C., Gierszewska M., Swanson S.K., Kesik-Brodacka M., Srivastava S., et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474(7353):658-661.
121. Goldstone D.C., Ennis-Adeniran V., Hedden J.J., Groom H.C., Rice G.I., Christodoulou E., et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011, (November).
122. Powell R.D., Holland P.J., Hollis T., Perrino F.W. The Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J Biol Chem 2011, (November).
123. Nisole S., Stoye J.P., Saïb A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 2005, 3(October (10)):799-808.
124. Neil S., Bieniasz P. Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res 2009, 29(September (9)):569-580.
125. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418(August (6898)):646-650.
126. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427(February (6977)):848-853.
127. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451(January (7177)):425-430.
128. Wolf D., Goff S.P. Host restriction factors blocking retroviral replication. Annu Rev Genet 2008, 42:143-163.
129. Hatziioannou T., Princiotta M., Piatak M., Yuan F., Zhang F., Lifson J.D., et al. Generation of simian-tropic HIV-1 by restriction factor evasion. Science 2006, 314(October (5796)):95.
130. Hatziioannou T., Ambrose Z., Chung N.P., Piatak M., Yuan F., Trubey C.M., et al. A macaque model of HIV-1 infection. Proc Natl Acad Sci USA 2009, 106(March (11)):4425-4429.
131. Uchida N., Washington K.N., Hayakawa J., Hsieh M.M., Bonifacino A.C., Krouse A.E., et al. Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells. J Virol 2009, 83(October (19)):9854-9862.
132. Owens C.M., Song B., Perron M.J., Yang P.C., Stremlau M., Sodroski J. Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J Virol 2004, 78(May (10)):5423-5437.
133. Rits M.A., van Dort K.A., Münk C., Meijer A.B., Kootstra N.A. Efficient transduction of simian cells by HIV-1-based lentiviral vectors that contain mutations in the capsid protein. Mol Ther 2007, 15(May (5)):930-937.
134. Kahl C.A., Cannon P.M., Oldenburg J., Tarantal A.F., Kohn D.B. Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIV-derived lentiviral vectors. Gene Ther 2008, 15(August (15)):1079-1089.
135. Arhel N.J., Nisole S., Carthagena L., Coutant F., Souque P., Brussel A., et al. Lack of endogenous TRIM5alpha-mediated restriction in rhesus macaque dendritic cells. Blood 2008, 112(November (9)):3772-3776.
136. Lim S.Y., Chan T., Gelman R.S., Whitney J.B., O'Brien K.L., Barouch D.H., et al. Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys. PLoS Genet 2010, 6(June (6)):e1000997.
137. Pal R., Venzon D., Letvin N.L., Santra S., Montefiori D.C., Miller N.R., et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 2002, 76(January (1)):292-302.
138. Mothé B.R., Weinfurter J., Wang C., Rehrauer W., Wilson N., Allen T.M., et al. Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 2003, 77(February (4)):2736-2740.
139. Newman R.M., Hall L., Connole M., Chen G.L., Sato S., Yuste E., et al. Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha. Proc Natl Acad Sci USA 2006, 103(December (50)):19134-19139.
140. Lim S.Y., Rogers T., Chan T., Whitney J.B., Kim J., Sodroski J., et al. TRIM5alpha modulates immunodeficiency virus control in rhesus monkeys. PLoS Pathog 2010, 6(January (1)):e1000738.
141. Wilson S.J., Webb B.L., Maplanka C., Newman R.M., Verschoor E.J., Heeney J.L., et al. Rhesus macaque TRIM5 alleles have divergent antiretroviral specificities. J Virol 2008, 82(July (14)):7243-7247.
142. Wilson S.J., Webb B.L., Ylinen L.M., Verschoor E., Heeney J.L., Towers G.J. Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc Natl Acad Sci USA 2008, 105(March (9)):3557-3562.
143. Brennan G., Kozyrev Y., Hu S.L. TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc Natl Acad Sci USA 2008, 105(March (9)):3569-3574.
144. Virgen C.A., Kratovac Z., Bieniasz P.D., Hatziioannou T. Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc Natl Acad Sci USA 2008, 105(March (9)):3563-3568.
145. Newman R.M., Hall L., Kirmaier A., Pozzi L.A., Pery E., Farzan M., et al. Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog 2008, 4(February (2)):e1000003.
146. Lama J., Planelles V. Host factors influencing susceptibility to HIV infection and AIDS progression. Retrovirology 2007, 4(July):52.